TTK inhibitors as a targeted therapy for β-catenin mutant cancers

被引：0
|
作者：
Zaman, Guido [1 ]
de Roos, Jeroen [1 ]
Libouban, Marion [1 ]
Prinsen, Martine [1 ]
de Man, Jos [1 ]
Buijsman, Rogier [1 ]
Uitdehaag, Joost [1 ]
机构：
[1] NTRC, Oss, Netherlands
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-B065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B065
引用
收藏
页数：2
相关论文
共 50 条
  • [1] TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers
    Zaman, Guido J. R.
    de Roos, Jeroen A. D. M.
    Libouban, Marion A. A.
    Prinsen, Martine B. W.
    de Man, Jos
    Buijsman, Rogier C.
    Uitdehaag, Joost C. M.
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (11) : 2609 - 2617
  • [2] KRAS-Mutant Lung Cancers in the Era of Targeted Therapy
    Naidoo, Jarushka
    Drilon, Alexander
    LUNG CANCER AND PERSONALIZED MEDICINE: CURRENT KNOWLEDGE AND THERAPIES, 2016, 893 : 155 - 178
  • [3] Recent advances in overcoming resistance to targeted therapy in KRAS mutant cancers
    Adachi, Yuta
    Niitsu, Hiroaki
    Ebi, Hiromichi
    CANCER SCIENCE, 2023, 114 : 986 - 986
  • [4] Wnt/β-catenin signaling in cancers and targeted therapies
    Yu, Fanyuan
    Yu, Changhao
    Li, Feifei
    Zuo, Yanqin
    Wang, Yitian
    Yao, Lin
    Wu, Chenzhou
    Wang, Chenglin
    Ye, Ling
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
  • [5] Wnt/β-catenin signaling in cancers and targeted therapies
    Fanyuan Yu
    Changhao Yu
    Feifei Li
    Yanqin Zuo
    Yitian Wang
    Lin Yao
    Chenzhou Wu
    Chenglin Wang
    Ling Ye
    Signal Transduction and Targeted Therapy, 6
  • [6] Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers
    Chai, Annie Wai Yeeng
    Yee, Pei San
    Cheong, Sok Ching
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [7] Developing inhibitors of BRAF and RAS mutant cancers
    Dalby, Kevin
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
  • [8] Tumor mutation burden and efficacy of targeted therapy in patients with EGFR mutant lung cancers.
    Offin, Michael David
    Rizvi, Hira
    Tenet, Megan
    Ni, Ai
    Vega, Francisco Sanchez
    Kris, Mark G.
    Rudin, Charles M.
    Riely, Gregory J.
    Yu, Helena Alexandra
    Hellmann, Matthew David
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Targeting β-Catenin in Hepatocellular Cancers Induced by Coexpression of Mutant β-Catenin and K-Ras in Mice
    Tao, Junyan
    Zhang, Rong
    Singh, Sucha
    Poddar, Minakshi
    Xu, Emily
    Oertel, Michael
    Chen, Xin
    Ganesh, Shanthi
    Abrams, Marc
    Monga, Satdarshan P.
    HEPATOLOGY, 2017, 65 (05) : 1581 - 1599
  • [10] Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers
    Sun, Chaoyang
    Fang, Yong
    Yin, Jun
    Chen, Jian
    Ju, Zhenlin
    Zhang, Dong
    Chen, Xiaohua
    Vellano, Christopher P.
    Jeong, Kang Jin
    Ng, Patrick Kwok-Shing
    Eterovic, Agda Karina B.
    Bhola, Neil H.
    Lu, Yiling
    Westin, Shannon N.
    Grandis, Jennifer R.
    Lin, Shiaw-Yih
    Scott, Kenneth L.
    Peng, Guang
    Brugge, Joan
    Mills, Gordon B.
    SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (392)
12345